Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

Yoneshima, Yasuto; Okamoto, Isamu; Arimura-Omori, Masako; Kimura, Shin-ichi; Hidaka-Fujimoto, Noriko; Iwama, Eiji; Harada, Taishi; Takayama, K.; Nakanishi, Yoichi

doi:10.1007/s10637-014-0195-1

Cited by 14 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 In mice kidneys, c-MET activation pathway decreased during the crizotinib treatment; it would seem to be aparadox. 11 Therefore by inhibiting c-MET pathway, crizotinib might stop the growth of pre-existing cystic lesions and prevent the onset of new renal ones. 9 This suggests that alternative pathways may be involved in cysts onset during the crizotinib treatment.…”

Section: Discussionmentioning

confidence: 99%

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

Mannetta

Carella

Grassadonia

et al. 2020

IMCRJ

View full text Add to dashboard Cite

Background: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. Case Presentation: We herein report the case of a 74-year-old woman who received crizotinib for metastatic ALK-positive NSCLC. During the crizotinib treatment, complex renal cystic lesions with invasion of perirenal spaces and iliopsoas muscle appeared; two complex hepatic cysts were also observed. Almost all lesions disappeared after switching to alectinib, a second-generation ALK inhibitor. Conclusion: It would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

Mannetta

Carella

Grassadonia

et al. 2020

IMCRJ

View full text Add to dashboard Cite

show abstract

“…Crizotinib has been associated with development of renal cysts [3], [4], [5], however, limited literature is available to describe its progression and imaging features due to novelty of this class of drug. Although crizotinib is used as a targeted selective inhibitor of ALK, it is a multikinase inhibitor of c-MET and ROS1 oncogenic tyrosine kinases.…”

Section: Discussionmentioning

confidence: 99%

“…Randomized control trials report positive progression-free survival and overall response in patients with disease progression after conventional chemotherapy. However, recent literature has reported complication of crizotinib with development of complex renal cysts [3], [4], [5].…”

Section: Introductionmentioning

confidence: 99%

Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report

Chan

Ang

Tan

et al. 2016

Radiology Case Reports

View full text Add to dashboard Cite

Crizotinib has been approved for the treatment of advanced ALK-positive non–small cell lung cancer. Its use is associated with the development of complex renal cysts. However, there is limited literature regarding imaging features of renal cystic disease during crizotinib therapy and its complications or progression. Here, we describe a case of a patient with ALK-positive advanced non–small cell lung cancer who developed complex renal cyst during crizotinib treatment. The renal cyst is complicated by infection and abscess formation. Subsequent renal biopsy, antibiotics treatment, and open drainage of loculated renal abscess showed no malignant cells and contributed to the diagnosis. The imaging features should be recognized as renal cystic disease of crizotinib treatment and not to be mistaken as new metastasis and disease progression.

show abstract

“…They did not report any pathologic agent in this case. Yoneshima et al [16] also described a case of a patient with aseptic renal abscess after treatment with Crizotinib in Japan.…”

Section: Discussionmentioning

confidence: 99%

Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment

Carvalho¹,

Shimada²,

Neto³

et al. 2015

ALC

View full text Add to dashboard Cite

Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and ROS1. In a safety database trial, it was suggested an association of Crizotinib with the development of renal cyst in patients with non-small-cell lung cancer (NSCLC). Aim: To report an uncommon side effect of Crizotinib in a patient with NSLC. Case Presentation: We report the case of a 68-year-old woman with NSCLC who developed bilateral progressive aseptic renal abscesses during Crizotinib treatment. Conclusion: Further studies may be necessary to determinate the risk of renal cyst development and the management of these complications.

show abstract

Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

Cited by 14 publications

References 9 publications

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report

Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment

Contact Info

Product

Resources

About